Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00217698 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00217698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00217698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2003
Completion date
October 31, 2004
Enrollment
63 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer